Overview of Non-clinical Assessment in Drug Development (8/14) REdI 2017
Рет қаралды 16,748
Күн бұрынHanan Ghantous covers the role and responsibilities of the pharmacology/toxicology reviewer related to the various components of the Investigational New Drug (IND) phase of drug development. This presentation covers both scientific and regulatory pharmacology/toxicology concepts that are part of the non-clinical submission to an IND/ NDA/BLA. Viewers will gain an understanding of animal studies submitted to support the safety of clinical studies and marketing applications.
-------------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cd...
CDER SBIA 2017 Playlist: • 2017 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cd...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367
U.S. Food and Drug Administration
Рет қаралды 6 М.
U.S. Food and Drug Administration
Рет қаралды 21 М.
U.S. Food and Drug Administration
Рет қаралды 12 М.
U.S. Food and Drug Administration
Рет қаралды 23 М.
U.S. Food and Drug Administration
Рет қаралды 28 М.
U.S. Food and Drug Administration
Рет қаралды 686
U.S. Food and Drug Administration
Рет қаралды 1,9 М.
U.S. Food and Drug Administration
Рет қаралды 9 М.
U.S. Food and Drug Administration
Рет қаралды 517
U.S. Food and Drug Administration
Рет қаралды 12 М.
U.S. Food and Drug Administration
Рет қаралды 329
U.S. Food and Drug Administration
Рет қаралды 11 М.